Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > CONCERN
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(56)
•••
Comment by RalphRalphon Jan 05, 2021 9:15pm
288 Views
Post# 32230090

RE:RE:RE:CONCERN

RE:RE:RE:CONCERN
To the contrary, I think you could replace Dan with the CEO of most any public biotech company and get at least equal job performance, if not markedly better.  I don't see any special value that he has provided to the company, but I do see numerous instances of poor decision-making. 
 
Truly 'fine' biotech CEOs deliver returns for shareholders (as reflected in stock price) & effectively monetize their pipeline assets.  Has Dan really done either of those things?  He is clearly the weak link in the management team.




Marky1 wrote: I think that Dan is doing a fine job! Give Dan, Stern and Dr. Stauffer a huge Thank You! By the end of January, I believe that ATE will be trading closer to its true value

Best of luck to all the longs!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities